Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02593123
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:50.036377+00:00
Published At
2023-01-23T00:00:00+00:00
Record Updated At
2023-01-23
Results Posted At
2023-01-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hodgkin\u0027s Lymphoma", "Lymphoid Leukemia", "Lymphoma", "Leukemia", "Myeloma", "Acute Lymphocytic Leukemia", "Non Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Multiple Myeloma", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndromes", "Recurrent Acute Myeloid Leukemia, Adult", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia", "Acute Myelogenous Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-01-23"
protocolSection.identificationModule.nctId
"NCT02593123"
protocolSection.identificationModule.officialTitle
"Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-01-23"

Study condition terms

  • Hodgkin's Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoid Leukemia (protocolSection.conditionsModule.conditions)
  • Lymphoma (protocolSection.conditionsModule.conditions)
  • Leukemia (protocolSection.conditionsModule.conditions)
  • Myeloma (protocolSection.conditionsModule.conditions)
  • Acute Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Non Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Multiple Myeloma (protocolSection.conditionsModule.conditions)
  • Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Myeloid Leukemia, Adult (protocolSection.conditionsModule.conditions)
  • Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Plasma Cell Myeloma (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Myelogenous Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.